<DOC>
	<DOCNO>NCT01997775</DOCNO>
	<brief_summary>The purpose study determine whether metformin effective lower plasma IL-6 level improve treatment response patient non-small cell lung cancer</brief_summary>
	<brief_title>Metformin Stage IV Lung Adenocarcinoma</brief_title>
	<detailed_description>Interleukin-6 ( IL-6 ) play important role pathogenesis lung cancer . Several clinical study show metformin could decrease IL-6 level addition glucose-lowering effect . Preclinical data also reveal metformin could decrease IL-6 production lung cancer cell enhance cytotoxicity chemotherapy animal model . Based finding , purpose study determine whether metformin effective lower plasma IL-6 level improve treatment response patient non-small cell lung cancer clinically . Patients stage IV lung adenocarcinoma enrol study receive standard treatment lung cancer , either chemotherapy combining cisplatin pemetrexed target therapy ( Gefitinib ) . For patient plasma IL-6 2.0 pg/ml 2 cycle standard treatment , metformin give titrate 1500mg/day gradually . Plasma IL-6 level check use metformin 12 week . Tumor response standard treatment plus metformin evaluated side effect metformin also monitor .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Histologically cytologically confirm lung adenocarcinoma . 2 . Stage IV disease define AJCC 7th edition staging . 3 . At least one measurable lesion ( defined RECIST v1.1 ) . 4 . No prior radiotherapy , chemotherapy , surgery , target therapy , immunotherapy NSCLC . ( Except surgery biopsy portA implantation , palliative localize radiotherapy bone metastasis ) . 5 . Age ≤ 80 year old ≥ 20 year old . 6 . ECOG performance status 02 . 7 . Adequate organ function , include following Bone marrow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ; WBC ≥ 3.0 x 10^9/L Platelet count ≥ 100 x 10^9/L Hemoglobin ≥ 9g/dL Hepatic : Total bilirubin level ≤ 1.0 x UNL AST ALT ≤ 3.0 x UNL ; Renal : Creatinine level ≤ 1.5 mg/dL men , ≤1.4 mg/dL woman ; Estimated CCr ≥ 60 mL/min . ( CCr estimate CockcroftGault formula , appendix II ) ( CCr estimate CockcroftGault formula ) 8 . Estimated life expectancy least 6 month . 9 . Written ( sign ) Informed Consent . 1 . With primary malignancy , except remain diseasefree 3 year curative treatment , basal cell cancer skin situ cervical cancer . 2 . Use anticancer therapy , include chemotherapy , target therapy , immunotherapy , radiotherapy , hormone therapy . 3 . Prior participation investigational drug study within 28 day . 4 . Use antiIL6 IL6lowering agent . 5 . Use metformin past 6 month . 6 . Poor control diabetes ( HbA1c ≥ 8.0 % ) . 7 . Known hypersensitivity intolerance metformin . 8 . Congestive heart failure NYHA functional class II~IV . 9 . History lactic acidosis . 10 . Significant concurrent medical disease , unstable angina , acute recent myocardial infarction ( &lt; 6 month enrollment ) , COPD frequent exacerbation , uncontrolled hypertension , recent CVA ( &lt; 6 month enrollment ) . 11 . Active uncontrolled infection HIV infection . 12 . Psychiatric disorder would compromise patient 's compliance decision . 13 . Current planned pregnancy , breast feeding woman . 14 . Poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>IL-6</keyword>
	<keyword>Metformin</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Lung adenocarcinoma</keyword>
</DOC>